← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sparian Biosciences, Inc.
New York City, NY
$32,032,282
Total funding
5
Grants
Funding over time
peak $8M · FY2021–25$10M$7.5M$5M$2.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,032,282 · 5
By mechanism
UG3$17,983,752 · 3
UH3$13,729,307 · 1
R44$319,223 · 1
Investigators at Sparian Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Arylepoxamides: A new class of potent, safer analgesics$4,628,029
UH3 · FY2022 · DA
Arylepoxamides: A new class of potent, safer analgesics$4,595,217
UH3 · FY2021 · DA
Arylepoxamides: A new class of potent, safer analgesics$4,506,061
UH3 · FY2023 · DA
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder$4,017,447
UG3 · FY2024 · DA
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD$3,984,629
UG3 · FY2025 · DA
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD$3,957,359
UG3 · FY2024 · DA
Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain$3,138,031
UG3 · FY2025 · DA
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder$2,886,286
UG3 · FY2023 · DA
Development of CP-analogs as novel treatments for opioid use disorder.$319,223
R44 · FY2021 · DA